biostudies-literatureUnknown157(10)Prinzi FLIn recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real-world analysis aims to evaluate the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer (BTCs) treated with cisplatin, gemcitabine and durvalumab (CGD) therapy. The study cohort included patients with a diagnosis of advanced BTCs who were taking concomitant medications for their comorbidities before the start of CGD. The primary objectives were overall survival (OS) and progression-free survival (PFS). The initial population consisted of 666 patients, who were retrospectively collected from 41 sites in 12 countries. Data on concomitant medications were avaInternational journal of cancer2092-2102https://www.ebi.ac.uk/biostudies/studies/S-EPMC12439076biostudies-literatureNegative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.PMC12439076Couto NDjaballah SAFinkelmeier FChan SLRizzato MDBartalini LGiordano GCastet FPrager GWLavacchi DSalani FAlvim CMKang MTamburini ETamberi SGrelli GDe Rosa ALandriscina MBekaii-Saab TSaborowski ADi Giacomo EVogel AKim JWNiger MDiana ABoccaccino ASchirripa MIkeda MTesini GRodriquenz MGMasi GGarajova IPrinzi FLKim IHQaisar AYoo CLonardi SRapposelli IGVerrico MCasadei-Gardini APeeters FPerkhofer LSatake TRimini MChiara PCamera SScartozzi MOneda EPressiani TGallio CBraconi CSpinelli GPTonini GParisi ARoque RHimmelsbach VPersoneni NAntonuzzo LRossari FAvallone AFornaro LFarinea GPolito MGBalsano RAbidoye OLucchetti JChon HJAdeva JLeo SDekervel JRimassa LPastorino AfalseNegative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real-world analysis aims to evaluate the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer (BTCs) treated with cisplatin, gemcitabine and durvalumab (CGD) therapy. The study cohort included patients with a diagnosis of advanced BTCs who were taking concomitant medications for their comorbidities before the start of CGD. The primary objectives were overall survival (OS) and progression-free survival (PFS). The initial population consisted of 666 patients, who were retrospectively collected from 41 sites in 12 countries. Data on concomitant medications were ava2025-01-01T00:00:00Z2025 Nov2026-04-08T19:50:38.143Z2026-04-08T14:35:05.081ZS-EPMC124390764064144810.1002/ijc.70009